APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and
erlotinib as measured by time to disease progression to test the hypothesis that down
regulation of COX-2 and EGFR pathways in patients with up-regulated COX-2 expression in tumor
will have a clinical benefit compared with erlotinib alone.